Hojjat Ahmadzadehfar

2 ta ish

Klinikum Westfalen (Germany)

1. Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers

   Majid Assadi, Seyed Javad Rekabpour, Esmail Jafari +9

   Maqola20213 iqtibos

   ABIABI:AkademIndex/2026.other.340322

2. Theranostics in nuclear medicine practice

   Anna Yordanova, Elisabeth Eppard, Stefan Kürpig +6

   Sharh maqolaOAOchiq kirishNeuroendocrine Tumor Research AdvancesOncoTargets and Therapy20170 iqtibos

   ABIABI:AkademIndex/2017.review-article.000002